Evaluating immune and clinical responses in early-stage triple negative breast cancer with chemo-immunotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study aims to assess the immune and clinical responses in patients with untreated Stage II-III triple negative breast cancer undergoing standard neoadjuvant chemo-immunotherapy. The primary objective is to determine if this treatment induces a specific pro-inflammatory cytokine profile in the blood shortly after treatment begins, which may correlate with a complete pathological response in the tumor. Secondary objectives include analyzing tissue samples for specific gene expression patterns that may indicate treatment outcomes. The study is observational and focuses on correlating immune responses with clinical results.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Newly diagnosed, previously untreated, non-metastatic Stage II-III invasive breast cancer
* Estrogen receptor IHC expression ≤10%; progesterone receptor IHC expression ≤ 10%; HER2 negative
* HER2 negativity is defined as either of the following by local laboratory assessment:
* IHC 0, 1+, or 2+ and In situ hybridization (ISH) non-amplified (ratio of HER2 to CEP17 \<2.0 or single probe average HER2 gene copy number \<4 signals/cell)
* No prior chemotherapy, endocrine therapy, or immunotherapy
* Willingness and ability of the subject to comply with scheduled visits, standard of care drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions.
* Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

* Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study
* Patients who are receiving any other investigational agents or an investigational device within 21 days before administration of first dose of study drugs.
* Patients on steroid medications (i.e. prednisone, dexamethasone, etc.) that are not part of the standard pre-medications and/or take home medications that are included as a part of medication regimen for the pre-operative chemo-immunotherapy described in the study.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in this study.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with study agents. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.

Where it's running

• Emory University/Winship Cancer Institute
  Atlanta, Georgia, United States Recruiting

Study contacts

• Principal investigator: Ruth Sacks, MD — Emory University Hospital/Winship Cancer Institute
• Study coordinator: Ruth Sacks, MD
• Email: rlsacks@emory.edu
• Phone: 404-778-1900

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SBRT with intratumoural pembrolizumab before neoadjuvant chemotherapy for high-risk breast cancer

  This study will test whether a short course of focused radiation plus two injections of pembrolizumab into the tumor before chemotherapy helps people with high‑risk invasive breast cancer respond better to treatment.

  Recruiting Phase 2 London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · London, Ontario and 1 other locations · NCT07188246

• Using tart cherry juice to prevent nerve damage from chemotherapy in breast cancer patients

  This study is testing if drinking tart cherry juice can help prevent nerve damage in breast cancer patients receiving chemotherapy.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT06268665

• Understanding how tumor shrinkage predicts cancer response in early breast cancer patients

  This study tests if measuring how much breast tumors shrink during chemotherapy can help predict how well the treatment will work for women with early-stage breast cancer.

  Recruiting at 2 sites Phase 2 Baylor Breast Care Center · Houston, Texas and 1 other locations · NCT05020860

• Capecitabine for MRD-positive, resected ER+/HER2-negative breast cancer

  This Phase 2 trial tests whether taking capecitabine can help people with resected, ER-positive/HER2-negative breast cancer who still have molecular residual disease after standard therapy.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT07631052

• Predicting how hormone therapy before surgery affects breast cancer

  This study is testing how hormone therapy before surgery can help people with early-stage breast cancer and what it means for their tumors.

  Recruiting Phase 2 George Washington University · Washington D.C., District of Columbia · NCT06806930

• Meal timing during cancer treatment for Alaska Native and American Indian patients

  This test will see if an 8-hour time-restricted eating schedule during neoadjuvant or adjuvant therapy helps Alaska Native and American Indian adults with rectal or certain breast cancers.

  Recruiting Fred Hutchinson Cancer Center · Anchorage, Alaska · NCT06802172

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.